Vir Biotechnology (VIR)

Executive Summary

Vir Biotechnology is a San Francisco-based clinical-stage immunology company specializing in antibody engineering and protease-releasable masking technology for infectious diseases and oncology. The company gained prominence through its rapid COVID-19 antibody program (sotrovimab) and has since pivoted to chronic viral infections and cancer. Key pipeline assets include a Phase 2 combination therapy (PEG-IFNα + BRII-835) for chronic hepatitis B, a Phase 2 regimen (VIR-2218 + VIR-3434) for hepatitis delta, and a Phase 3 program (tobevibart + elebsiran) for viral hepatitis. In oncology, Vir is advancing Phase 1 candidates VIR-5500 for prostate cancer and VIR-5525 for EGFR-positive solid tumors. While the company has faced headwinds from declining COVID-related revenues, its strategic focus on hepatitis delta (a high-unmet-need indication) and emerging oncology data provide potential value inflection points. Upcoming catalysts include top-line safety and efficacy data from the Phase 2 hepatitis B study (PEG-IFNα + BRII-835), which completed enrollment in early 2026. Additionally, interim results from the Phase 2 hepatitis delta trial (VIR-2218 + VIR-3434) are expected in mid-2026, with functional cure data being a key catalyst. Early dose-escalation data from the Phase 1 oncology programs (VIR-5500 and VIR-5525) are also anticipated in the second half of 2026, which could validate Vir's platform expansion into solid tumors. The company's cash position and partnership with Brii Bio provide runway to reach these milestones.

Upcoming Catalysts (preview)

• Q2 2026Phase 2 hepatitis B data (PEG-IFNα + BRII-835) top-line results60% success
• Q3 2026Interim Phase 2 hepatitis delta data (VIR-2218 + VIR-3434)55% success
• H2 2026Phase 1 oncology dose-escalation data (VIR-5500 and/or VIR-5525)40% success